Jorge Conde

Jorge Conde is the founder of Tafkak, Inc. (founded in 2007) and currently holds positions as Director at Octant, Inc., Director at Aria Pharmaceuticals, Inc., Director at Tmunity Therapeutics, Inc., Director at Asimov, Inc., Director at IDRx, Inc., Partner at AH Capital Management LLC (since 2017), Board Member at Komodo Health, Inc. (since 2020), and Board Member at Dyno Therapeutics, Inc. (since 2021).
He previously served as an Independent Director at EQRx, Inc. (from 2020 to 2023) and CAMP4 Therapeutics Corp.
(from 2018 to 2024).
Prior to his current and former positions, Mr. Conde held roles as Manager-Operations & Marketing at MedImmune LLC, Investment Banker at Morgan Stanley, and Head-Business Development at Helicos Biosciences Corp.
He also served as Chief Strategy Officer at Syros Pharmaceuticals, Inc. from 2016 to 2017.
Mr. Conde received his undergraduate degree from The Johns Hopkins University, his graduate degree from Harvard Mit Health Sciences & Technology, and his MBA from Harvard Business School in 2005.